Cargando…

A novel mineralocorticoid receptor antagonist, 7,3',4'-trihydroxyisoflavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids

Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC-induced cutaneous adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hanil, Choi, Eun-Jeong, Kim, Eun Jung, Son, Eui Dong, Kim, Hyoung-June, Park, Won-Seok, Kang, Young-Gyu, Shin, Kyong-Oh, Park, Kyungho, Kim, Jin-Chul, Kim, Su-Nam, Choi, Eung Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184959/ https://www.ncbi.nlm.nih.gov/pubmed/34099793 http://dx.doi.org/10.1038/s41598-021-91450-6

Ejemplares similares

7,3′,4′-Trihydroxyisoflavone Ameliorates the Development of Dermatophagoides farinae-Induced Atopic Dermatitis in NC/Nga Mice
por: Kim, Bo-Bae, et al.
Publicado: (2013)

7,3′,4′-Trihydroxyisoflavone, a Metabolite of the Soy Isoflavone Daidzein, Suppresses α-Melanocyte-Stimulating Hormone-Induced Melanogenesis by Targeting Melanocortin 1 Receptor
por: Kim, Ji Hye, et al.
Publicado: (2020)

Design of acid-responsive polymeric nanoparticles for 7,3′,4′-trihydroxyisoflavone topical administration
por: Huang, Pao-Hsien, et al.
Publicado: (2016)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Improvement of Skin Penetration, Antipollutant Activity and Skin Hydration of 7,3′,4′-Trihydroxyisoflavone Cyclodextrin Inclusion Complex
por: Huang, Pao Hsien, et al.
Publicado: (2019)

Antineuroinflammatory Effects of 7,3’,4’-Trihydroxyisoflavone in Lipopolysaccharide-Stimulated BV2 Microglial Cells through MAPK and NF-κB Signaling Suppression
por: Kim, Seon-Kyung, et al.
Publicado: (2021)

7,8,4′-Trihydroxyisoflavone Attenuates DNCB-Induced Atopic Dermatitis-Like Symptoms in NC/Nga Mice
por: Kim, Heejung, et al.
Publicado: (2014)

The Daidzein Metabolite, 6,7,4'-Trihydroxyisoflavone, Is a Novel Inhibitor of PKCα in Suppressing Solar UV-Induced Matrix Metalloproteinase 1
por: Lim, Tae-Gyu, et al.
Publicado: (2014)

Preparation, characterizations and anti-pollutant activity of 7,3′,4′-trihydroxyisoflavone nanoparticles in particulate matter-induced HaCaT keratinocytes
por: Huang, Pao-Hsien, et al.
Publicado: (2018)

Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy
por: Howard, Zachary M., et al.
Publicado: (2022)

Exogenous Ceramide Serves as a Precursor to Endogenous Ceramide Synthesis and as a Modulator of Keratinocyte Differentiation
por: Shin, Kyong-Oh, et al.
Publicado: (2022)

Mineralocorticoid Antagonist Improves Glucocorticoid Receptor Signaling and Dexamethasone Analgesia in an Animal Model of Low Back Pain
por: Ibrahim, Shaimaa I. A., et al.
Publicado: (2018)

Roles of the Glucocorticoid and Mineralocorticoid Receptors in Skin Pathophysiology
por: Sevilla, Lisa M., et al.
Publicado: (2018)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

GLUCOCORTICOID-INDUCED HYPERTENSION AND CARDIAC INJURY: EFFECTS OF MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ANTAGONISM
por: HATTORI, TAKUYA, et al.
Publicado: (2013)

Glucocorticoid Receptor–Tethered Mineralocorticoid Receptors Increase Glucocorticoid-Induced Transcriptional Responses
por: Rivers, Caroline A, et al.
Publicado: (2019)

Benign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids
por: Yoon, Vivienne, et al.
Publicado: (2013)

Blunted glucocorticoid and mineralocorticoid sensitivity to stress in people with diabetes
por: Carvalho, Livia A., et al.
Publicado: (2015)

Glucocorticoid and Mineralocorticoid Receptors in the Brain: A Transcriptional Perspective
por: Koning, Anne-Sophie C A M, et al.
Publicado: (2019)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

7,8,4′-Trihydroxyisoflavone, a Metabolized Product of Daidzein, Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells
por: Ko, Yong-Hyun, et al.
Publicado: (2019)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonism Attenuates Multiple Organ Failure after Renal Ischemia and Reperfusion in Mice
por: Park, Eun Jung, et al.
Publicado: (2023)

One Hormone for Two Receptors: Exploring Glucocorticoid Actions Mediated by the Glucocorticoid and Mineralocorticoid Receptors
por: Petrillo, Maria G, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment
por: Kim, Jin Young, et al.
Publicado: (2018)

Structural analysis of the evolution of steroid specificity in the mineralocorticoid and glucocorticoid receptors
por: Baker, Michael E, et al.
Publicado: (2007)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
por: Chin, Eric K, et al.
Publicado: (2015)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Glucocorticoid-dependent transcription in skin requires epidermal expression of the glucocorticoid receptor and is modulated by the mineralocorticoid receptor
por: Sevilla, Lisa M., et al.
Publicado: (2020)

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells
por: Clarisse, Dorien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t5mubgvlqatjigk2fod0b95q3p